Company Quick10K Filing
Avedro
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 17 $335
10-Q 2019-11-06 Quarter: 2019-09-30
10-Q 2019-08-08 Quarter: 2019-06-30
10-Q 2019-05-09 Quarter: 2019-03-31
S-1 2019-01-18 Public Filing
10-K 2019-03-21 Annual: 2018-12-31
8-K 2019-11-19 M&A, Shareholder Rights, Control, Officers, Amend Bylaw, Shareholder Vote, Other Events, Exhibits
8-K 2019-11-15 Officers, Other Events, Exhibits
8-K 2019-11-08 Other Events
8-K 2019-11-06 Earnings, Exhibits
8-K 2019-08-07 Enter Agreement, Earnings, Officers, Other Events, Exhibits
8-K 2019-05-09 Earnings, Exhibits
8-K 2019-03-21 Earnings, Exhibits
8-K 2019-02-19 Amend Bylaw, Other Events, Exhibits

Avedro Financials

AVDR Metrics, Comps, Filings

Annual | Quarterly

Business

Our Avedro Corneal Remodeling Platform technology uses corneal cross-linking to strengthen the cornea and modify its shape, a process we refer to as corneal remodeling. Because the cornea functions as the eye's outermost lens, responsible for 65% to 75% of the eye's total focusing power, we believe corneal remodeling represents a powerful approach to treating corneal ectatic disorders and correcting vision. We believe corneal remodeling is a particularly effective treatment for progressive keratoconus, a disease in which the cornea progressively thins and weakens, as corneal remodeling strengthens and stabilizes the cornea to slow or arrest the progression of the disease. Corneal remodeling can also potentially be used to correct vision for otherwise healthy individuals by reshaping the cornea through a non-invasive procedure without the need for corneal surgical procedures.

The broad utility of our platform in treating corneal ectatic disorders and correcting vision has the potential to enable us to target a population that we estimate to be approximately 64 million people in the United States, which represents an estimated total addressable market opportunity of $26 billion. Our initial commercial focus within the United States is the keratoconus market, which, according to a recent Market Scope study from 2018, we believe represents a total addressable market of approximately 600,000 people and an opportunity of approximately $3 billion. Keratoconus typically manifests at an early age and is the leading cause of full thickness corneal transplants in the United States, a procedure that costs an average of $20,000 per transplant and may require one or more repeat procedures in the same eye later in life. Unlike corneal cross-linking, non-surgical solutions, such as eyeglasses or contact lenses, do not treat the underlying cause of keratoconus or slow disease progression, but temporarily attempt to address its symptoms, such as poor vision.

We estimate the vision correction market for our products in the United States to be approximately 63 million people, or an estimated total addressable market opportunity of $23 billion. Our initial clinical focus in vision correction is the treatment of patients with presbyopia, which we estimate affects more than 50 million people in the United States, representing an estimated total addressable market opportunity of approximately $15 billion. Vision correction procedures traditionally include refractive surgery or implants, the most common of which is laser in-situ keratomileusis, or LASIK. While LASIK is the most common vision correction procedure, we believe that it has not achieved greater market penetration due to patients' fears of an ablative laser procedure and the associated side effects. Although we currently do not have any FDA-approved products to treat presbyopia, we believe that our Mosaic system, which is currently available in non-U.S. jurisdictions, addresses the critical challenges of currently available vision correction procedures, as corneal remodeling does not involve cutting or ablating the cornea. In addition to presbyopia, we are exploring the use of our Mosaic system as a treatment option for other large markets in the United States, including correcting refractive error for low myopia, which we estimate affects 13.5 million people, representing a total addressable market opportunity of approximately $8 billion, and post-cataract procedures, which we estimate affects 600,000 eyes annually, representing a total annual addressable market opportunity of approximately $180 million.


Valuation ($)

Market Cap, Enterprise Value

Balance Sheet ($)

Assets, Stockholders' Equity

Income Statement ($ Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($ Annual)

Operating, Investing, Financing

Comps ($ TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Semler Scientific (SMLR) 357,642,604,000 88% 44.3 75% 9,824,000,000 3,603,000,000 20,293,000,000 17,897,000,000 7,329,000,000 7,970,000,000 353,460,603,000
Gulfmark Offshore (GLF) 354,229,140,000 0% 26.1 -6% 417,402,000,000 135,430,000,000 78,633,000,000 0 -27,052,000,000 15,946,000,000 416,697,140,000
PHH (PHH) 354,128,361,000 0% -0.2 -10% 1,442,000,000,000 953,000,000,000 315,000,000,000 0 -138,000,000,000 -149,000,000,000 37,128,361,000
Government Properties Income Trust (GOV) 349,784,738,000 0% 1.3 -2% 4,804,322,000,000 3,107,836,000,000 176,032,000,000 0 -88,899,000,000 255,390,000,000 325,099,737,000
Nuzee (NUZE) 346,483,290,000 8% -23.3 -247% 6,056,516,000 984,330,000 1,674,689,000 128,528,000 -14,953,892,000 -14,780,993,000 343,685,834,000
JEM Capital (JEM) 345,931,500,000 -4,033.1 -13,053% 660,000 110,820,000 0 0 -86,149,000 -85,774,000 345,931,335,000
Fellazo (FLLZ) 345,056,000,000 -2,070.3 -807% 20,648,000 680,395,000 0 0 -166,669,000 -166,669,000 345,056,000,000
Kraig Biocraft Laboratories (KBLB) 342,650,874,000 0% -263.9 -124% 1,276,033,000 5,343,298,000 140,761,000 0 -1,581,701,000 -1,296,092,000 341,976,645,000
ETFS Silver Trust (SIVR) 337,258,500,000 28.0 4% 334,676,000,000 83,000,000 0 0 12,035,000,000 12,035,000,000 337,258,500,000
Kaleido Biosciences (KLDO) 335,102,063,000 -5.7 -41% 109,997,000,000 25,371,000,000 0 0 -44,858,000,000 -43,716,000,000 247,815,063,000
Avedro (AVDR) 334,795,409,000 73% -20.6 -20% 78,952,000,000 28,911,000,000 19,062,000,000 13,997,000,000 -15,781,000,000 -14,375,000,000 296,719,409,000
New York & Company (NWY) 330,377,520,000 30% 171.7 -2% 488,888,000,000 421,105,000,000 860,882,000,000 261,954,000,000 -11,662,000,000 1,439,000,000 247,057,520,000
NextCure (NXTC) 325,729,730,000 0% -10.1 -7% 213,050,000,000 34,455,000,000 2,759,000,000 0 -14,376,000,000 -13,132,000,000 133,001,730,000
Invesco DB US Dollar Index Bullish Fund (UUP) 322,276,000,000 14.1 7% 328,380,011,000 6,444,626,000 0 0 22,845,728,000 22,873,089,000 322,228,248,000
SciPlay (SCPL) 311,217,000,000 66% 9.6 8% 337,000,000,000 116,400,000,000 118,100,000,000 77,600,000,000 26,200,000,000 27,300,000,000 260,816,999,000
Corium (CORI) 305,899,985,000 0% -4.9 -50% 112,131,000,000 87,239,000,000 37,693,000,000 0 -56,540,000,000 -45,465,000,000 223,762,985,000
Exantas Capital (RSO) 303,720,090,000 0% 19.4 1% 2,519,737,000,000 1,961,785,000,000 60,298,000,000 0 35,602,000,000 113,727,000,000 2,203,721,090,000
Energy XXI Gulf Coast (EGC) 300,174,460,000 0% -1.3 -30% 1,032,246,000,000 929,173,000,000 454,101,000,000 0 -313,739,000,000 -174,942,000,000 228,492,460,000
Harpoon Therapeutics (HARP) 299,110,667,000 0% -6.7 -16% 157,016,000,000 34,543,000,000 3,189,000,000 0 -25,396,000,000 -24,796,000,000 165,210,666,000
Zynex (ZYXI) 295,051,570,000 81% 21.5 45% 21,839,000,000 7,772,000,000 38,026,000,000 30,679,000,000 9,725,000,000 13,285,000,000 284,997,569,000

Balance Sheet ($)
Cash
Accounts Receivable
Inventory
PP&E
Assets
Accounts Payable
Long-Term Debt
Liabilities
Stockholders' Equity
Income Statement ($)
Revenue
Cost of Revenue
Gross Profit
R&D
SG&A
Tax
Net Income
Cash Flow ($)
Cash Operating
Cash Investing
Cash Financing